2020
Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection
Peluso MJ, Colby DJ, Pinyakorn S, Ubolyam S, Intasan J, Trichavaroj R, Chomchey N, Prueksakaew P, Slike BM, Krebs SJ, Jian N, Robb ML, Phanuphak P, Phanuphak N, Spudich S, Ananworanich J, Kroon E, , Teeratakulpisarn N, Pattanachaiwit S, Sacdalan C, Sriplienchan S, de Souza M, Tantivitayakul P, Poltavee K, Luekasemsuk T, Savadsuk H, Tipsuk S, Puttamsawin S, Benjapornpong K, Ratnaratorn N, Tangnaree K, Munkong C, Thaimanee R, Eamyoung P, Buranapraditkun S, Lerdlum S, Manasnayakorn S, Rerknimitr R, Sirivichayakul S, Wattanaboonyongcharoen P, Suttichom D, O'Connell R, Schuetz A, Hsu D, Akapirat S, Nuntapinit B, Tantibul N, Churikanont N, Getchalarat S, Michael N, Vasan S, Crowell T, Turk E, McCullough C, Butterworth O, Milazzo M, Anne Eller L. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. Journal Of The International AIDS Society 2020, 23: e25444. PMID: 31953919, PMCID: PMC6968973, DOI: 10.1002/jia2.25444.Peer-Reviewed Original ResearchConceptsAcute HIV infectionLiver function test abnormalitiesBaseline alanine aminotransferaseAntiretroviral therapyHIV infectionAlanine aminotransferaseALT elevationALT levelsTest abnormalitiesCopies/Baseline plasma HIV RNA levelElevated baseline alanine aminotransferasePlasma HIV RNA levelsBaseline ALT levelsBaseline HIV RNAConcomitant viral hepatitisEfavirenz-based regimensFiebig stage IIIFiebig stages IGrade 1 elevationImmediate antiretroviral therapyHIV RNA levelsEarly HIV infectionCombination of HIVThai individuals
2019
Treatment of Central Nervous System Manifestations of HIV in the Current Era
Handoko R, Spudich S. Treatment of Central Nervous System Manifestations of HIV in the Current Era. Seminars In Neurology 2019, 39: 391-398. PMID: 31378874, DOI: 10.1055/s-0039-1688915.Peer-Reviewed Original ResearchConceptsCSF HIVTreatment intensificationCentral nervous system opportunistic infectionsHuman immunodeficiency virus (HIV) infectionCentral nervous system manifestationsCurrent ARV regimenHIV resistance mutationsNeuropsychiatric adverse effectsImmunodeficiency virus infectionNervous system manifestationsNeuropsychiatric side effectsMagnetic resonance imagingCerebrospinal fluid dataSystemic HIVHigh CNS penetrationARV regimenSystem manifestationsOpportunistic infectionsHIV replicationTreatment switchLumbar punctureSleep disturbancesVirus infectionCCR5 inhibitorsNeuropsychiatric impairmentPredicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment
Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price R, Spudich S, Swanstrom R, Kashuba A. Predicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. Clinical And Translational Science 2019, 12: 302-311. PMID: 30675981, PMCID: PMC6510381, DOI: 10.1111/cts.12620.Peer-Reviewed Original ResearchConceptsBrain tissue concentrationsCerebrospinal fluidBrain tissueRhesus macaquesNeurocognitive scoresPK/pharmacodynamic analysesPenetration of antiretroviralsTissue concentrationsExposure-response analysisConcentration-time curveAdult rhesus macaquesCSF AUCEfavirenz concentrationsPlasma AUCPharmacodynamic analysisClinical studiesTissue AUCNeurocognitive impairmentCSF samplesPharmacokinetic dataPK modelingHIVTime pointsAUCNecropsy